Pace Life Sciences Expands Capacity and Capability With Acquisition of Catalent's Analytical Services Laboratory in Research Triangle Park
Catalent Stock: Is CTLT Outperforming the Healthcare Sector?
Catalent Cut to Neutral at Baird as Analyst Unable to Find Valuation in a Deal Break
Catalent Analyst Ratings
Baird Downgrades Catalent to Neutral From Outperform, Price Target Is $63.50
Baird Downgrades Catalent(CTLT.US) to Hold Rating, Maintains Target Price $63.5
Baird analyst Eric Coldwell downgrades $Catalent(CTLT.US)$ to a hold rating, and maintains the target price at $63.5.According to TipRanks data, the analyst has a success rate of 53.9% and a total
Hold Rating on Catalent Amid Deal Uncertainties and Conservative Financial Outlook
Sword of Justice! The US FTC sues three major pharmaceutical "middlemen", vows to correct the distorted profit chain.
The USA's FTC announced on its official website that it has filed a lawsuit against three major "pharmacy benefit managers" and their affiliated organizations, accusing them of engaging in anti-competitive and unfair kickback practices. FTC also "clearly stated" in the declaration its deep concern about the roles played by eli lilly and co, novo-nordisk a/s, sanofi, and other insulin pharmaceutical companies, and the competition bureau may recommend prosecuting these pharmaceutical companies in future enforcement actions.
UBS Highlights 30 Stocks Poised for Potential Moves After the Fed's Expected Rate Cut
Do Options Traders Know Something About Catalent (CTLT) Stock We Don't?
J&J Leads H1 Healthcare Deals as Big Pharma Dealmaking Returns: Report
Catalent (CTLT) Upgraded to Strong Buy: Here's What You Should Know
Decoding Catalent Inc (CTLT): A Strategic SWOT Insight
Catalent | 10-K: FY2024 Annual Report
Contract Development & Manufacturing Organization (CDMO) Market Insights & Forecast 2024-2028, Featuring Profiles of Catalent, Recipharm, Evotec, Lonza, Biomerieux and Thermo Fisher Scientific - ResearchAndMarkets.com
Catalent Delays 10-K Filing
Express News | Catalent Inc Says Files Non-Timely 10-K With U.S. SEC
Is Catalent (NYSE:CTLT) A Risky Investment?
Morgan Stanley Fund: Will the pharmaceutical stocks "counterattack" as the Federal Reserve cuts interest rates?
Morgan Stanley Fund said that if the Federal Reserve cuts interest rates, risk appetite for funds may increase, and innovative drugs with higher growth potential may receive more risk capital favor in the short to medium term, gaining some upward momentum.
American Injectables CEO Beau Garrett Comments on the Catalent-Novo Transaction: A Catalyst for Competition and Innovation